Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness
Clinical Questions Addressed by This Comparative Effectiveness Review (3 of 3)
This comparative effectiveness review attempted to address four key questions. Key Questions (KQs) 3 and 4 are listed on this slide:
KQ 3: This question has two parts:
a. What are the comparative harms associated with antiviral treatments?
b. Do these harms differ according to patient subgroup characteristics, including hepatitis C virus (HCV) genotype, age, race, sex, stage of disease, or genetic markers?
KQ4: Have improvements in intermediate outcomes (sustained virologic response; histologic changes) been shown to reduce the risk or rates of adverse health outcomes from HCV infection?
- Chou R, Hartung D, Rahman B, et al. Treatment for Hepatitis C Virus Infection in Adults: A Comparative Effectiveness Review. Evidence Report No. 76 (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC113-EF. Available at www.effectivehealthcare.ahrq.gov/hepctreatment.cfm.
Your slide tray is being processed.